Tagged with Strategy,

Pharma Hetero, the global API leader, has consolidated its position as the partner of choice of the pharmaceutical industry in Mexico, with a portfolio of more than 300 APIs. GM Gurulinga Konanuris is piloting entry into the B2C market, with upcoming launches of biosimilars, oncology and HIV treatments. Hetero is also investing…

Pharma Janssen Switzerland’s Ludo Ooms highlights the strengths of the Swiss healthcare and life sciences sector including the efficiency of the government, a productive and well trained workforce, the national pricing system, and the climate for innovation; all factors which make Switzerland a strategic market for Johnson & Johnson and Janssen.…

Health Alberto Hechanova, president of the Drugstore Association of the Philippines (DSAP), discusses the competitive landscape of the country, highlighting the main challenges and opportunities for independent drugstores. In addition, he explains why being a member of the association can impact business success. Mr Hechanova, could you please introduce yourself and…

Pharma Daniel Pardo Bejarano, CEO of BOMI Mexico, details the competitive advantages and the unique business approach that make BOMI the logistics partner of choice of the Mexican healthcare industry, while the fast-growing company holds the ambition to double the size of its business over the next four years. After more…

Biotech The chairman of BioSingapore, Dr. Siew Hwa Ong, discusses the opportunities and challenges facing biotech SMEs in Singapore, government efforts to enhance the business environment for these SMEs, and facilitating more collaboration between companies as the most prominent pathway for future development. Could you please introduce yourself to our international…

Italy Italy’s traditional family-owned pharmaceutical companies are one of its greatest strengths; but these companies must be amenable to outside influence in order to grow sustainably. [There is] a lot of liquidity in the market, including amongst the family businesses … and there are now a lot of companies looking for…

Pharma The Singapore Association of Pharmaceutical Industries’ (SAPI) recently appointed president, Ti Hwei How highlights several unique attributes that distinguish Singapore’s renowned healthcare system from others around the world, while delineating three potential avenues for expanding patient access to innovative medicines. To begin, Ti Hwei, how would you characterize the specificities…

Healthcare In light of the recently released OECD Reviews of Health Systems: Mexico 2016, Roberto Martinez, general director of the OECD Mexico Center for Latin America, reveals the OECD’s key findings and strategic priorities for fostering inclusive growth and better health outcomes in Mexico, while the Center keeps on strengthening its…

Pharma The expansion of universal healthcare coverage and significant growth in the use and acceptance of generics across the Philippines pose a significant challenge to the innovative medicines industry but also offers a wealth of opportunities for both international and domestic players. The Philippines now utilizes low-cost generics more than any…

Pharma Francisco González, CEO of ProMéxico, the Mexican investment agency, describes the strengths of Mexico’s research and industrial base, untapped business opportunities in the pharmaceutical and healthcare sectors, and new export horizons in Africa and Asia. Mexico currently displays a very interesting business context: the economy is back to robust growth…

Pharma The general manager of ALK Czech Republic and Slovakia on his strategy which led to success within the first one and a half years of ALK’s physical presence in the cluster. Furthermore, he highlights the significance of having the right people in the right place and positioning the company as…

Pharma Xavier Valdez analyses the dynamics impacting the Mexican pharmaceutical market and explains why IMS Health is transforming itself to strengthen its position as the partner of choice for decision-makers throughout the entire value chain. How would you assess the performance of the Mexican pharmaceutical market for 2015? From 2014 to 2015,…